Elsevier MDL lance une nouvelle version am?lior?e de sa plate-forme DiscoveryGate destin?e ? accro?tre la productivit? de la recherche

cette nouvelle version constitue un puissant environnement de recherche et développement à l’intention des milieux pharmaceutique et universitaire, plus rapide et plus simple à installer et utiliser

Presse économique / Santé / Médical

SAN LEANDRO, Californie -- (BUSINESS WIRE) -- June 13, 2005 -- Elsevier MDL a le plaisir d’annoncer le lancement d’une version améliorée de DiscoveryGate, la plate-forme de contenus largement reconnue de la société, destinée à la recherche en chimie et sciences de la vie. Mettant à profit les meilleures qualités de la technologie MDL® Isentris®, la nouvelle plate-forme DiscoveryGate offre un niveau de performance et de convivialité d’utilisation amélioré, permettant aux chercheurs d’accéder rapidement à des informations scientifiques critiques provenant d’un vaste éventail de sources.

( BW)(CA-ELSEVIER-MDL)(RUK)(ENL)(REN.EU)(REL.L) Elsevier MDL Releases Major DiscoveryGate Upgrade to Boost Research Productivity; Powerful Discovery Environment for Pharma and Academia is Faster, Easier to Install and Use

Business Editors/Health/Medical Writers

SAN LEANDRO, Calif.--(BUSINESS WIRE)--June 13, 2005--Elsevier MDL is pleased to announce the release of an enhanced version of DiscoveryGate, the company's highly acclaimed content platform for chemistry and life sciences research. Leveraging MDL(R) Isentris(R) technology, the new DiscoveryGate provides improved performance and usability -- helping researchers rapidly find critical scientific information from a broad array of sources

"With more than 300 customers and thousands of users, DiscoveryGate is already a significant success in the global pharma and biotech R&D arenas," said Elsevier MDL CEO Lars Barfod.

"Customer requirements for improved productivity played a key role in this major upgrade, which provides faster responses to complex queries, improved usability and easy installation and maintenance. DiscoveryGate continues to demonstrate the impressive enterprise-scale capabilities of the MDL Isentris development framework for science." DiscoveryGate (www.discoverygate.com) integrates information from 25 chemistry and pharmacology databases on a single hosted platform, providing direct links to the primary literature and integration with customers' internal systems

For any given search, the platform provides comprehensive results in the context of the original query.

For example, researchers querying specific reaction databases can use new "Also Found In" links to simultaneously retrieve related information from other chemistry, molecular biology, bioactivity, metabolism/toxicology, chemical sourcing and synthetic methodology databases

The database links extend to important new sources including the xPharm(R) database, which is the world's largest pharmacological reference work, and MDL(R) Patent Chemistry Database, an extensive new reaction and factual database for scientists in chemistry and the life sciences.

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products.

For more information, visit www.mdl.com.

Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

For more information visit www.elsevier.com

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

For more information visit www.reedelsevier.com.

MDL, Isentris and DiscoveryGate are registered trademarks of MDL Information Systems, Inc. ("Elsevier MDL") in the United States and/or other countries.

All rights reserved.

CONTACT:

Elsevier MDL

Dr. Phil McHale, 510-357-2222 ext. 3541 email: [email protected]